Showing 851-860 of 19239 results for "".
Does an IV Hydration Therapy Practice Need a Medical Director?
https://modernaesthetics.com/ma-issues-index/2022-nov-dec/does-an-iv-hydration-therapy-practice-need-a-medical-director/35231/It’s important to understand requirements in your state.A Resurgence of Stents
https://reachmd.com/programs/diabetes-discourse/a-resurgence-of-stents/4693/Diabetes is strongly linked with a number of risk factors for coronary problems such as high blood pressure, high cholesterol, abdominal obesity that significantly increases the risk of heart attack and stroke. Recent studies indicate that new drug-eluting stents are a reasonable option for the diabParticle Number Testing in the Prevention of Atherosclerosis
https://reachmd.com/programs/lipid-luminations/particle-number-testing-in-the-prevention-of-atherosclerosis/5189/What is the role of advanced lipid testing, and particle number testing in particular? How might this information change the way you treat your patients? Host Dr. Alan Brown talks with Dr. Tara Dall, medical director of Advanced Lipidology Early Detection Center for Heart Disease and Diabetes in DelCardiometabolic Risk Reduction in Native Americans
https://reachmd.com/programs/lipid-luminations/cardiometabolic-risk-reduction-in-native-americans/5987/Joining host Dr. Alan Brown, Ralph LaForge, clinical exercise physiologist at Duke University in the department of endocrinology, and senior faculty consultant to the diabetes division of the US Indian Health Service, discusses the health issues of the Native American population, and some of the novPolycystic Ovary Disease
https://reachmd.com/programs/lipid-luminations/polycystic-ovary-disease/3180/Host Dr. Larry Kaskel welcomes Dr. Tara Dall, board-certified lipidologist at Advanced Lipidology in Wisconsin, to discuss chronic anovulation and hyperandrogenism, and its association with an increased risk of diabetes, metabolic syndrome and cardiac problems. She will also highight treatIFPA World PsO and PsA Conference
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/ifpa-world-pso-and-psa-conference/29084/The International Federation of Psoriasis Associations (IFPA) hosted its 7th World Psoriasis and Psoriatic Arthritis Conference in late June in Stockholm, Sweden. Topics covered included genetics/immunology, prevention of psoriatic arthritis, understanding pain and itch, treatment advances in topicaDecoding Proteinuria: A Window into Kidney Health in IgAN
https://reachmd.com/programs/clinicians-roundtable/decoding-proteinuria-a-window-into-kidney-health-in-igan/27029/Explore how protein levels in urine can help predict long-term kidney health in patients with IgAN.Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.New Treatments in IBD – Professional Webinar Series
https://reachmd.com/programs/cme/new-treatments-in-ibd-professional-webinar-series/15694/Join us for this module of the IBD Pro Webinar Series presentation titled “New Treatments in IBD”. The talk will include new medications, positioning, real world evidence, and the Foundation's EMR IBD Education Tool. The 45 minute presentation will be followed by a 15 minute question and answer sEarly Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
https://reachmd.com/clinical-practice/dermatology/early-onset-of-response-to-zasocitinib-tak-279-a-highly-selective-and-potent-tyk2-inhibitor-is-correlated-with-modulation-of-tyk2-signaling-and-disease-pathway-biomarkers-in-patients-with-moderate-to-severe-plaque-psoriasis/50977/Review phase 2b trial data on zasocitinib in patients with moderate-to-severe plaque psoriasis.